Plain-English translation of NCT06585982 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a supplement called RILLUS, which contains beneficial bacteria and fiber, to see if it can help people with metabolic dysfunction-associated fatty liver disease (a condition where fat builds up in the liver due to problems with how the body processes sugar and fat). Researchers believe that the healthy bacteria in this medication may improve how the body handles insulin and reduce inflammation in the liver.
Fatty liver disease affects millions of people worldwide and is often connected to obesity, diabetes, and problems with metabolism. Early research suggests that the balance of bacteria in your gut plays an important role in liver health, and this treatment may help restore that balance and reduce liver damage.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the RILLUS supplement or a placebo (inactive pill) that looks identical. Over the study period, you will take your assigned tablet daily and keep a diary recording whether you took it each day. You will likely have visits where researchers check your liver health, measure insulin and inflammation markers in your blood, and collect information about your gut bacteria, but the exact schedule will be provided when you enroll.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Indonesia